 The FDA has placed a partial clinical hold on Curis Incs NASDAQ: CRIS TakeAim Lymphoma study. The TakeAim Lymphoma study is a Phase 12 open-label dose-escalating clinical trial investigating emavusertib in patients with B-cell malignancies. 